On 13 January 2026, the Parliamentary Group against Antimicrobial Resistance (PKAMR) met at the German Bundestag to discuss how to improve access to antibiotics in low- and middle-income countries (LMICs), while also strengthening incentives for the development of urgently needed new treatments.
The Global AMR R&D Hub was glad to take part in this discussion, with Dr. Ralf Sudbrak and Suzanne Edwards contributing to the exchange. In his welcome address, Dr. Sudbrak highlighted the urgent need to address global inequities in access to antibiotics, noting that limited availability of effective treatments in LMICs is not only a local challenge but a broader global health risk.
The discussion also included perspectives from MSF, GARDP, and Shionogi, focusing on persistent barriers to access such as delayed availability, affordability constraints, and weak health system capacity. Speakers also explored how “pull incentives” and new partnership models can support innovation while ensuring equitable access and responsible use.
A shared message throughout the session was clear: innovation and access must be addressed together to effectively respond to AMR.
